Chemoradiotherapy-Induced Severe Oral Mucositis Clinical Trial
— VOICEOfficial title:
A Phase 2b/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Clonidine Mucoadhesive Buccal Tablet to Placebo to Prevent Chemoradiotherapy-induced Severe Oral Mucositis in Patients With Oropharyngeal Cancer
| Verified date | May 2023 |
| Source | Monopar Therapeutics |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This study is being performed to evaluate the effectiveness of a new drug, clonidine HCl MBT, to prevent the onset of severe oral mucositis (SOM) in patients with oropharyngeal cancer (OPC) who are being treated with chemoradiotherapy. OPC occurs on the back of the tongue or throat and is often treated by the use of chemoradiotherapy, where radiation is localized to these areas. Radiation to the OPC affected tissues causes the release of small proteins called cytokines that cause damage to the area surrounding the tumor including the oral cavity. This damage is characterized by the formation of mucositis which includes redness, pain and ulcers in the mouth and back of the throat. In addition, as more chemoradiation is administered to treat OPC, the inability to eat a solid diet (a Grade 3 mucositis) or to consume anything at all by mouth (a Grade 4 mucositis) occurs in many patients. Collectively, Grade 3 and Grade 4 mucositis is referred to as SOM. It is a frequent, debilitating side effect of chemoradiation in OPC that may cause patients to stop or interrupt their treatment, develop other side effects like the inability to swallow, or require the increased use of pain medications. OPC survivors who have successful treatment of their tumors often develop permanent swallowing, speaking and range of motion issues that may be linked back to the inability to eat and/or drink caused by SOM during their chemoradiotherapy treatment. Clonidine may inhibit the production of cytokines that cause SOM and clonidine HCl mucoadhesive buccal tablet (MBT) has been designed to deliver sustained high levels of clonidine in the oral cavity, potentially decreasing cytokine production and leading to a decrease in the incidence of SOM. Clonidine HCl MBT is a once per day treatment provided as a tablet that a patient may self-administer to the gums, where it sticks tightly to release clonidine over many hours. The primary objective of this Phase 2b/3 study is to evaluate whether clonidine HCl MBT is more effective than placebo MBT in decreasing the incidence of SOM.
| Status | Terminated |
| Enrollment | 190 |
| Est. completion date | May 14, 2023 |
| Est. primary completion date | May 14, 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: 1. Male/Female patients of = 18 years of age. Patients with histologically or pathologically confirmed squamous cell carcinoma of the oropharynx (including tonsils or the base of tongue) at one or several sites. 2. Patients treated with surgical resection of their primary tumor for localized or locally advanced disease T = T0 and/or N = N1 without distant metastasis (M0) (American Joint Committee on Cancer - AJCC 8th edition) and initiating adjuvant concurrent CRT within 8 weeks post-operatively. Unknown primary with node-positive disease confirmed to be Squamous Cell Carcinoma would be allowed or Patients who will be treated with definitive concurrent CRT for locally advanced disease T = T0 and/or N = N1 M0 (American Joint Committee on Cancer - AJCC 8th edition). 3. Patients eligible to receive a continuous course of external fractionated irradiation [conventional or intensity modulated radiation therapy (IMRT)] based on a daily dosing of 1.8 to 2.2 Gy/day 5 days/week in combination with cisplatin monotherapy either every 3 weeks (100 mg/m2) or weekly cisplatin (40 mg/m2). Alternative treatment regimens are allowed only if cisplatin is contraindicated. The decision on which cisplatin regimen to use in combination with IMRT and study drug/placebo will be at the discretion of the investigator. 4. Radiation plan must include delivery of a cumulative dose of 60-72 Gy. The oropharynx should receive at least 50 Gy. 5. Patients with adequate laboratory values defined as: 1. Absolute neutrophil count = 1.5 × 10^9/L 2. Platelet count = 75 × 10^9/L 3. Hemoglobin = 9 g/dL 4. Creatinine blood level = 1.5 × upper limit of the normal range (ULN) 5. Total bilirubin = 1.5 × ULN; patients with Gilbert's Syndrome can be included if hyperbilirubinemia = 3 × ULN 6. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3 × ULN 6. Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. A performance status of 2 is allowed only if due to a patient's malignancy. 7. Patients must provide written informed consent. 8. Human Papillomavirus (HPV) status documented by immunohistochemical detection of p16 expression in the tumor. 9. Negative serum pregnancy test for females of child-bearing potential at screening. A female is eligible to enter and participate in the study if the female is of non-child-bearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has had a hysterectomy, a bilateral oophorectomy (ovariectomy), a bilateral tubal ligation, or is post-menopausal with a minimum of 1 year without menses. 10. Males with female partners of child-bearing potential and females of child-bearing potential must agree to use effective contraception starting prior to the first day of study drug treatment and continuing for 3 months after the last dose of study drug MBT. 11. Patients must be willing to complete questionnaires on a tablet, home computer, or paper form. Exclusion Criteria: 1. Patients with no tumor or lesion in the oropharynx. 2. Prior induction chemotherapy for treatment of current malignancy. 3. Patients with planned accelerated IMRT. 4. Evidence of a concomitant other malignancy and/or any prior malignancy without complete remission in the last 2 years, except adequately treated basal or squamous cell carcinoma of the skin or in situ cervical cancer. 5. Patients with OM at baseline, any other oral ulceration or active oral infection (e.g., aphthous ulcers, orofacial herpes). Patients with post-operative pain of the mouth or throat are eligible. 6. Patients with known human immunodeficiency virus (HIV) seropositivity, known active Hepatitis B or C or known active tuberculosis. 7. Patients with systolic blood pressure (BP) < 100 mmHg and/or diastolic BP < 50 mmHg. 8. Patients with symptomatic cardiac dysrhythmia. 9. Patients with recent (less than 6 months) acute cardiovascular diseases (i.e., stroke, myocardial infarction). 10. Patients with any clinical condition, psychiatric condition, or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with study requirements and follow-up visits. 11. Patients currently being treated with sultopride, clonidine hydrochloride (eg, Catapres®), pentoxifylline or pilocarpine. 12. Patients intended to be treated specifically to prevent OM with any of the following: a. Bioadherent agents and mouthwashes: i. GelClair (consists of polyvinylpyrrolidone, hyaluronic acid, and glycyrrhetinic acid) ii. Sucralfate iii. Episil mouth spray iv. MuGard oral mucoadhesive v. Saforis (L-glutamine (topical)) b. Drug therapies and biologics: i. Amifostine (and similar free radical scavenger/antioxidant medications) ii. Palifermin (recombinant human keratinocyte growth factor-(KGF-1)) iii. Glutamine b. Interventional therapies i. Low level laser therapy (LLLT) 13. Patients who are unable to tolerate oral diet and/or are feeding tube dependent at baseline. 14. Patients receiving an approved or an investigational anti-cancer agent other than those specified in this study. 15. Patients with a known hypersensitivity to clonidine or any of the MBT excipients. 16. Women who are pregnant or breast-feeding. 17. Patients whose medical, psychological or surgical conditions are unstable and may affect the study completion and/or compliance and/or the ability to give informed consent. 18. Men and women of child-bearing age and their respective partners unwilling to use a highly effective contraception method during the study and for 3 months after the last administration of study drug. 19. Patient who has participated in another clinical trial with an investigational drug in the last 30 days prior to randomization in the present clinical study. 20. Subjects with orthostatic hypotension, defined by a decrease of systolic BP and/or diastolic BP above 20 mmHg when the patient stands up. 21. Conditions including but not limited to COVID-19 which would confound the assessment of the effects and/or safety of study medication in the opinion of the investigator. |
| Country | Name | City | State |
|---|---|---|---|
| France | Centre Hospitalier Universitaire Amiens-Picardie | Amiens | |
| France | Centre Hospitalier Universitaire Morvan / Centre Hospitalier Universitaire de Brest | Brest | |
| France | Institut Andree Dutreix / Centre de Cancerologie Dunkerque | Coudekerque-Branche | Dunkerque |
| France | Centre hopitalier intercommunal de Créteil | Créteil | |
| France | Centre Hospitalier de Dax-Côte d'Argent | Dax | |
| France | Clinique François Chénieux | Limoges | |
| France | Hôpital Saint Joseph | Marseille | |
| France | Centre Hospitalier Universitaire La miletrie | Nice | |
| France | Institut Jean Godinot | Reims | |
| France | CHU de Saint Etienne | Saint-Priest-en-Jarez | |
| France | Institut Gustave Roussy, Desmoulins | Villejuif | |
| Germany | Universitatsklinikum Freiburg | Freiburg | |
| Germany | Klinikum Kassel GmbH | Kassel | |
| Germany | Caritas Klinikum Saarbrucken St. Theresia | Saarbrücken | |
| Puerto Rico | Ponce Medical School Foundation | Ponce | |
| Spain | Hospital Universitario Cruces de Bilbao | Barakaldo | Bizkaia |
| Spain | Hospital Universitari Vall d'Hebron | Barcelona | |
| Spain | Institut Català d'Oncologia Hospitalet (Hospital Duran i Reynals) | Barcelona | |
| Spain | Hospital Universitario Quirónsalud Madrid | Madrid | |
| Spain | Hospital Universitario Puerta de Hierro Majadahonda | Majadahonda | |
| Spain | Hospital Universitari Son Espases | Palma | Balearic Islands |
| Spain | Hospital Universitari Son Llàtzer | Palma De Mallorca | |
| Spain | Hospital Complejo Universitario de Navarra | Pamplona | |
| Spain | Hospital de Donostia | San Sebastián | |
| Spain | Hospital Clínico Universitario Santiago de Compostela | Santiago de Compostela | |
| Spain | Hospital Meixoeiro | Vigo | Pontevedra |
| United States | Hendrick Cancer Center | Abilene | Texas |
| United States | Summa Health System | Akron | Ohio |
| United States | University Cancer & Blood Center | Athens | Georgia |
| United States | Greater Baltimore Medical Center | Baltimore | Maryland |
| United States | PeaceHealth | Bellingham | Washington |
| United States | Boca Raton Regional Hospital | Boca Raton | Florida |
| United States | UnityPoint Health | Cedar Rapids | Iowa |
| United States | University of North Carolina at Chapel Hill | Chapel Hill | North Carolina |
| United States | Charleston Oncology | Charleston | South Carolina |
| United States | Novant Health Cancer Institute | Charlotte | North Carolina |
| United States | University of Cincinnati Medical Center | Cincinnati | Ohio |
| United States | IACT Health (Centricity Research) | Columbus | Georgia |
| United States | Decatur Memorial Hospital | Decatur | Illinois |
| United States | Des Moines Oncology Research Association | Des Moines | Iowa |
| United States | Henry Ford Health System | Detroit | Michigan |
| United States | Edward Elmhurst Health | Elmhurst | Illinois |
| United States | NorthShore University Health Systems | Evanston | Illinois |
| United States | Providence Regional Cancer Partnership | Everett | Washington |
| United States | Summit Health | Florham Park | New Jersey |
| United States | Orange Coast Memorial Medical Center | Fountain Valley | California |
| United States | CaroMont Regional Medical Center | Gastonia | North Carolina |
| United States | Grand Valley Oncology | Grand Junction | Colorado |
| United States | HSHS St. Vincent Hospital Cancer Centers at HSHS St. Vincent Hospital | Green Bay | Wisconsin |
| United States | AMITA Health | Hinsdale | Illinois |
| United States | Ballad Health | Johnson City | Tennessee |
| United States | University of Arkansas for Medical Sciences | Little Rock | Arkansas |
| United States | Long Beach Memorial Medical Center | Long Beach | California |
| United States | East Jefferson General Hospital | Metairie | Louisiana |
| United States | Miami Cancer Institute | Miami | Florida |
| United States | New York Cancer and Blood Specialists | New York | New York |
| United States | Northwell Health | New York | New York |
| United States | Christiana Care Health Services | Newark | Delaware |
| United States | Eastern Virginia Medical School | Norfolk | Virginia |
| United States | Stephenson Cancer Center | Oklahoma City | Oklahoma |
| United States | Memorial Healthcare System | Pembroke Pines | Florida |
| United States | Thomas Jefferson University | Philadelphia | Pennsylvania |
| United States | AHN Cancer Institute - Allegheny General | Pittsburgh | Pennsylvania |
| United States | Mary Hillman Radiation Oncology Center at UPMC Shadyside | Pittsburgh | Pennsylvania |
| United States | Pomona Valley Hospital Medical Center | Pomona | California |
| United States | Rhode Island Hospital | Providence | Rhode Island |
| United States | Benaroya Research Institute at Virginia Mason | Seattle | Washington |
| United States | Louisiana State University Health - Shreveport | Shreveport | Louisiana |
| United States | Willis-Knighton Cancer Center | Shreveport | Louisiana |
| United States | Cox Medical Centers | Springfield | Missouri |
| United States | Oklahoma Cancer Specialists | Tulsa | Oklahoma |
| United States | Reading Hospital | West Reading | Pennsylvania |
| United States | Novant Health Cancer Institute - Forsyth | Winston-Salem | North Carolina |
| United States | Mercy Health | Youngstown | Ohio |
| Lead Sponsor | Collaborator |
|---|---|
| Monopar Therapeutics |
United States, France, Germany, Puerto Rico, Spain,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | To demonstrate the efficacy of HCl MBT to prevent SOM in OPC patients receiving CRT. | The occurrence of SOM (Yes/No), defined as any reporting of World Health Organization (WHO) Grade 3-4 OM, from the first day to the last day of CRT. The WHO mucositis grading scale will be used to assess the occurrence of SOM in this trial. The WHO grading scale grades OM from 0 to 4 according to severity of clinical observation and functional limitation, with Grade 4 = oral alimentation impossible, Grade 3 = Oral ulcers, liquid diet only, Grade 2 = Oral erythema, ulcers, solid diet tolerated, Grade 1 = Oral soreness, erythema, and Grade 0 = normal, no mucositis (no signs, no symptoms). | From the first CRT treatment through the end of the study treatment period, which is estimated to be 7 weeks. | |
| Secondary | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Evaluate the safety and tolerability of administering HCl MBT to OPC patients receiving CRT by assessing the number and severity of treatment-emergent adverse events (TEAE) and specifically those TEAEs of special interest. Adverse events are graded and tabulated using NCI CTCAE v5.0. | Up to 1 year after the first dose |